Medical

Oragenics said that it has initiated a Phase 2a trial of ONP-002, a dry powder intranasal neurosteroid, for the treatment of mild traumatic brain injury in Australia after receiving approval from the Human Research Ethics… Read more . . .

According to Dompé, researchers at the Agostino Gemelli IRCCS University Hospital in Rome, Italy have initiated a Phase 2 trial of Dompé’s intranasal formulation of cenegermin-bkbj, a recombinant human nerve growth factor, in patients with… Read more . . .

According to United Therapeutics, the Phase 3 TETON-1 trial of nebulized Tyvaso treprostinil inhalation solution in patients with idiopathic pulmonary fibrosis met its primary endpoint, demonstrating a 130.1 mL change in absolute FVC from baseline to… Read more . . .

According to Tonix Pharmaceuticals, researchers at Erasmus University Medical Center have initiated a Phase 1 study of Tonix’s TNX-1900 intranasal potentiated oxytocin in healthy female volunteers as a proof of concept for the potential use… Read more . . .

In April 2025, Avalyn Pharma announced plans to advance its AP02 nintedanib inhalation solution into a Phase 2 trial in patients with idiopathic pulmonary fibrosis. Avalyn has now announced the initiation of the Phase 2… Read more . . .

According to Insmed, the Phase 3b ENCORE study of once-daily Arikayce amikacin liposome inhalation suspension plus azithromycin and ethambutol in patients with newly diagnosed Mycobacterium avium complex (MAC) lung infection met its primary endpoint. The study demonstrated a… Read more . . .

Interna Therapeutics has announced that under an agreement with the University of Oxford researchers led by Oxford’s Helen McShane will conduct a Phase 2a study of the company’s intranasal molecular nano-motor (MNM)-siRNA drug against SARS-CoV-2.… Read more . . .

Nexalis Therapeutics, which recently changed its name from InhaleRx, has announced the initiation of a Phase 1 trial of its IRX-616a cannabidiol MDI, which the company is developing for the treatment of panic disorder. In… Read more . . .

Nasus Pharma announced that topline data from its Phase 2 trial of NS002 intranasal dry powder epinephrine versus EpiPen intramuscular epinephrine “demonstrated multiple significant advantages for NS002 across key pharmacokinetic and pharmacodynamic parameters.” The company… Read more . . .

Rein Therapeutics announced the that the first patient has been dosed in a Phase 2 study evaluating its LTI-03 caveolin-1 scaffolding domain peptide DPI in patients with idiopathic pulmonary fibrosis, with interim data expected later… Read more . . .